Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley J Goldsmith

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Case Reports in Oncology|November 25, 2011
Isolated splenic metastasis from rectal carcinoma: a rare occurrenceSarika Jain, Sumeet Munjal, Rhonda K Yantiss, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Pancreas|July 29, 2010
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and CecumJ Philip Boudreaux, David S Klimstra, Manal M Hassan, et al.
Leukemia & Lymphoma|February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Leukemia & Lymphoma|April 10, 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford, Biree Andemariam, Shibu M Philips, et al.
Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Cell Metabolism|August 7, 2009
PET imaging of leptin biodistribution and metabolism in rodents and primatesGiovanni Ceccarini, Robert R Flavell, Eduardo R Butelman, et al.
Cancer|April 24, 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancerScott T Tagawa, Shankar Vallabhajosula, Paul J Christos, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Case Reports in Oncology|November 25, 2011
Isolated splenic metastasis from rectal carcinoma: a rare occurrenceSarika Jain, Sumeet Munjal, Rhonda K Yantiss, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?Shankar Vallabhajosula, Ichei Kuji, Klaus A Hamacher, et al.
The Journal of Urology|October 9, 2003
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigenNeil H Bander, Edouard J Trabulsi, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2005
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomasRichard I Fisher, Mark S Kaminski, Richard L Wahl, et al.
Pancreas|July 29, 2010
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and CecumJ Philip Boudreaux, David S Klimstra, Manal M Hassan, et al.
Leukemia & Lymphoma|February 28, 2007
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvementJodi V Mones, Morton Coleman, Lale Kostakoglu, et al.
Leukemia & Lymphoma|April 10, 2008
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphomaSarah C Rutherford, Biree Andemariam, Shibu M Philips, et al.
Cancer|December 20, 2005
Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphomaAlan D Dosik, Morton Coleman, Lale Kostakoglu, et al.
Cell Metabolism|August 7, 2009
PET imaging of leptin biodistribution and metabolism in rodents and primatesGiovanni Ceccarini, Robert R Flavell, Eduardo R Butelman, et al.
Cancer|April 24, 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancerScott T Tagawa, Shankar Vallabhajosula, Paul J Christos, et al.
Pageof 7